TY - JOUR T1 - Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes JF - medRxiv DO - 10.1101/2022.08.03.22278392 SP - 2022.08.03.22278392 AU - Yasin Abul AU - Frank Devone AU - Thomas A Bayer AU - Christopher Halladay AU - Kevin McConeghy AU - Nadia Mujahid AU - Mriganka Singh AU - Ciera Leeder AU - Stefan Gravenstein AU - James L. Rudolph Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/04/2022.08.03.22278392.abstract N2 - Background/Objectives Coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state and increased thrombotic risk in infected individuals. Several complex and varied coagulation abnormalities were proposed for this association1. Acetylsalicylic acid(ASA, aspirin) is known to have inflammatory, antithrombotic properties and its use was reported as having potency to reduce RNA synthesis and replication of some types of coronaviruses including human coronavirus-299E (CoV-229E) and Middle East Respiratory Syndrome (MERS)-CoV 2,3. We hypothesized that chronic low dose aspirin use may decrease COVID-19 mortality relative to ASA non-users.Methods This is a retrospective, observational cohort analysis of residents residing at Veterans Affairs Community Living Centers from December 13, 2020, to September 18, 2021, with a positive SARS-CoV-2 PCR test. Low dose aspirin users had low dose (81mg) therapy (10 of 14 days) prior to the positive COVID date and were compared to aspirin non-users (no ASA in prior 14 days). The primary outcome was mortality at 30 and 56 days post positive test and hospitalization.Results We identified 1.823 residents who had SARS-CoV-2 infection and 1,687 residents were eligible for the study. Aspirin use was independently associated with a reduced risk of 30 days of mortality (adjusted HR, 0.60, 95% CI, 0.40-0.90) and 56 days of mortality (adjusted HR, 0.67, 95% CI, 0.47-0.95)Conclusion Chronic low dose aspirin use for primary or secondary prevention of cardiovascular events is associated with lower COVID-19 mortality. Although additional randomized controlled trials are required to understand these associations and the potential implications more fully for improving care, aspirin remains a medication with known side effects and clinical practice should not change based on these findings.Competing Interest StatementThis work was supported by the Center of Innovation in Long-Term Services and Supports for Vulnerable Veterans, VA Providence Health Care System, Providence, RI, and the Office of Academic Affiliations Fellowship ProgramFunding StatementThis work was supported by the Center of Innovation in Long-Term Services and Supports for Vulnerable Veterans, VA Providence Health Care System, Providence, RI, and the Office of Academic Affiliations Fellowship ProgramAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Providence VAMC IRB and R&D committeesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe secondary analysis of clinical data was approved by the Providence VAMC IRB and R&D committees. Data release is governed by the VA Data Policy and is unable to be released at this time. ER -